Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.